From Malaria to COVID-19: Sixty Degrees Pharma CEO Geoff Dow's Perspective on Infectious Disease Solutions

Learn about Sixty Degrees Pharma (Nasdaq: SXTP) from CEO Geoff Dow. In this exclusive interview with Dow, gain insight into the company's mission to develop and commercialize new therapies for a range of infectious diseases, including its FDA-approved malaria preventative treatment ARAKODA® and the Company's current pipeline development programs for Tafenoquine and Celgosivir targeting COVID-19, fungal, tick-borne, and other viral diseases. Learn more about this game-changing small-cap stock by visiting SXTPinfo.com today.

0:00 - start
0:16 - Overview
2:30 - Products
5:02 - Addressable Markets
6:15 - Data
7:25 - Product Comparisons
8:07 - Upcoming Milestones
8:57 - Management
10:20 - Essential Value Prop